行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

0.7000
-0.0330
-4.50%
已收盘, 16:00 11/12 EST
开盘
0.7000
昨收
0.7330
最高
0.8000
最低
0.6600
成交量
9.20万
成交额
--
52周最高
4.400
52周最低
0.4900
市值
1,265.56万
市盈率(TTM)
-0.5575
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NAVB 新闻

  • Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.4天前
  • Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.4天前
  • Navidea Biopharmaceutical Q3 Sales $236.811K Up From $231.458K YoY
  • Benzinga.5天前
  • Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
  • Business Wire.5天前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

NAVB 简况

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
展开

Webull提供Navidea Biopharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。